section name header

Pronunciation

rye-oh-SIG-ue-at

Classifications

Therapeutic Classification: pulmonary hypertension agents

Pharmacologic Classification: soluble guanylate cyclase stimulators (sGS)

Indications

REMS


Action

  • Stimulates soluble guanylate cyclase, a cardiopulmonary enzyme and receptor for nitric oxide, which when stimulated produces cyclic guanine monophosphate, an important regulator of vascular tone, proliferation, fibrosis, and inflammation. This pathway is dysregulated in pulmonary hypertension.
Therapeutic effects:
  • Improved symptoms/exercise tolerance and delayed worsening.

Pharmacokinetics

Absorption: Well absorbed following oral administration (94%)

Distribution: Unknown.

Protein Binding: 95%

Metabolism/Excretion: Extensively metabolized by the liver via the CYP1A1, CYP3A, CYP2C8, and CYP2J2 isoenzymes; M1 metabolite is pharmacologically active; metabolites are excreted in urine and feces.

Half-Life: 12 hr

Time/Action Profile

(improvement in 6-min walk distance)

ROUTEONSETPEAKDURATION
POwithin 2 wk8–16 wkunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension

GI: dyspepsia, gastritis, nausea, vomiting, constipation, diarrhea, gastroesophageal reflux, liver enzymes

Hemat: anemia, BLEEDING

Neuro: dizziness, headache

Resp: pulmonary edema ( in veno-occlusive disease)

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Adempas